Pharma News

Merck , known as MSD outside the United States and Canada, issued  the following statement after the conclusion of a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) to discuss the results of IMPROVE-IT, an investigational study comparing treatment with VYTORIN® (ezetimibe and simvastatin) to treatment with simvastatin alone in more than 18,000 patients presenting with acute coronary syndromes.

AstraZeneca and its global biologics research and development arm, MedImmune,  announced a three-year collaboration with the newly established Wallenberg Centre for Protein Research (WCPR). The collaboration aims to develop new technologies for biologics production and to identify new targets for disease research in the ground-breaking area of the Secretome - research into all proteins that are secreted by a cell or that are exposed to the outside of the cell from within the cell membrane.

AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies designed for the treatment of acute pain, reported on the outcome of the ARX-04 (sufentanil sublingual tablet, 30 mcg) pre-NDA meeting held recently with the U.S. Food and Drug Administration (FDA).

Contrary to popular assumption -- and a talk by actor Arnold Schwarzenegger at the United Nations Paris Climate Change Conference -- eating a vegetarian diet could contribute more to climate change than eating a non-vegetarian diet, warns a new study.

Looking at why providing food is not always enough to treat malnutrition in developing countries, researchers have discovered that damage to the gut from infection can cause malnutrition and vaccine failure.

[adsense:336x280:8701650588]

Scientists have discovered a gene mutation that may trigger muscle and heart disorders, said a study.

The U.S. Food and Drug Administration  approved Vistogard (uridine triacetate) for the emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or capecitabine, or who develop certain severe or life-threatening toxicities within four days of receiving these cancer treatments.

The U.S. Food and Drug Administration approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib).